Mass Tort Advertising Campaign

Suboxone Tooth Decay Marketing & Claimant Acquisition

Suboxone — the buprenorphine/naloxone sublingual film manufactured by Indivior — has been linked to severe dental decay and tooth loss in patients who used the medication as directed. Because the film dissolves under the tongue, prolonged exposure is alleged to create an acidic oral environment that destroys enamel, often leaving users with catastrophic dental damage they never anticipated when starting treatment. Plaintiff firms are actively pursuing claims against Indivior on behalf of individuals who suffered these injuries.

For plaintiff-side marketing teams, this tort carries strong acquisition fundamentals: a single, identifiable manufacturer, a discrete product form (sublingual film, not tablet), a vivid and documentable injury, and a claimant population that used a legal, prescribed medication and had no reason to expect dental destruction as a side effect. Intake is open, and MTAA is currently running and available to run paid Meta campaigns for firms in this space.

Book a strategy call All tort campaigns

Suboxone Tooth Decay at a glance

Substance / mechanism: Buprenorphine/Naloxone sublingual film
Manufacturer(s): Indivior
Associated injuries: Severe Dental Decay, Tooth Loss
Campaign intake: Open

The litigation landscape

Litigation against Indivior centers on allegations that the company failed to adequately warn patients and prescribers that the sublingual film formulation of Suboxone could cause severe dental decay and tooth loss. The injury profile is medically concrete — enamel erosion, cavities, cracked and lost teeth — and distinguishable from ordinary dental neglect, which matters both for case quality and for creative messaging. Claimants are individuals who were prescribed Suboxone film as part of opioid use disorder treatment, used it for an extended period, and emerged with dental damage disproportionate to any pre-existing condition.

The product-specific nature of the claims is a meaningful litigation detail: the sublingual film delivery mechanism is central to the alleged harm, which means the borderline of the case universe is relatively well-defined. Firms building dockets want claimants who used the film formulation — not tablet alternatives — and who can document the severity of their dental injuries. That specificity translates directly into tighter, higher-converting intake criteria on the advertising side.

Who a campaign targets

Product used: Suboxone sublingual film (buprenorphine/naloxone) — not tablet formulations
Duration of use: Campaigns are structured to surface claimants with six or more months of film use, where the alleged exposure and resulting damage are most defensible
Injury severity: Target claimants present with severe dental decay, significant tooth loss, or both — injuries that go well beyond routine cavities and are documentable through dental records
Dental history: The strongest claimant profile involves individuals without a prior history of severe dental disease, so that the Suboxone film use is the most plausible causal factor — campaigns and intake scripts are calibrated to screen on this point
Borderline cases: Claimants who used tablet formulations or who have significant pre-existing dental disease present qualification challenges and should be flagged for attorney review rather than auto-qualified

How MTAA runs Suboxone Tooth Decay campaigns

The creative opportunity here is rooted in a powerful and relatable injustice: people who followed their doctor's instructions to treat opioid dependency — a courageous and medically supervised step — and ended up losing their teeth. That narrative is emotionally resonant without being exploitative, and it travels well on Facebook and Instagram because it speaks to a real, visible harm that claimants can immediately recognize in their own experience. Ad creative focuses on the specific product (the dissolving film under the tongue), the unexpected nature of the dental damage, and the legitimacy of pursuing accountability against the manufacturer. This is not a lifestyle-disease tort — the injury is discrete, the product is named, and the defendant is a corporation, which keeps the messaging clean and the audience self-selecting.

On the audience side, Meta's interest and behavioral signals allow MTAA to reach individuals who have engaged with opioid recovery content, medication-assisted treatment communities, and dental health topics — a combination that surfaces the right claimant profile without broad, wasteful spend. Intake flow for this tort benefits from a short, specific qualifier sequence: film versus tablet, duration of use, and dental injury severity. That brevity keeps drop-off low and allows firms to move quickly from lead to retained client. MTAA builds the full funnel — ad creative, landing page, and intake handoff — around these qualification points so that the volume firms receive is pre-screened and actionable.

Pricing

Mass Tort Ad Agency runs Suboxone Tooth Decay campaigns on the same transparent model as every tort: actual Meta ad spend at cost plus a flat 15% management fee, a one-time $1,000 setup fee per tort, and $100 per signed retainer for CloudIntake qualification. No per-case markups, no lead resale, and the firm owns its ad account, pixel, creative, and claimant data.

Suboxone Tooth Decay advertising — common questions

Why is the film formulation distinction so important for our advertising campaign?

The alleged mechanism of injury — prolonged sublingual acid exposure from the dissolving film — is specific to the film delivery format, not Suboxone tablets. Campaigns built around this distinction naturally filter toward the stronger end of the case universe and reduce intake noise from claimants whose product use doesn't align with the core liability theory. MTAA builds this qualifier into both ad creative and landing page copy so that claimants self-select before they ever reach your intake team.

How does MTAA handle the pre-existing dental disease screening issue at the top of the funnel?

We incorporate dental history as a soft qualifier in the intake flow — framed conversationally rather than as a hard gate — so that your team receives flagged information on each lead rather than a binary pass/fail that might discard borderline claimants worth a second look. Claimants who disclose significant prior dental disease are routed to a separate queue for attorney review, keeping your strong-case pipeline clean while preserving optionality on the edges.

What does the claimant audience look like on Meta for this tort, and is it large enough to scale?

Suboxone film has been prescribed to a substantial population of patients in medication-assisted treatment programs across the United States, and that population has meaningful overlap with Meta's recoverable audience segments around opioid recovery, chronic health conditions, and dental health. We layer interest signals, behavioral data, and lookalike modeling to build a targetable audience that scales as budget increases. Because the injury is visible and the product is named, creative performance tends to be strong relative to more diffuse tort categories.

Is this tort competitive enough on Meta that CPLs will be prohibitive for a firm entering now?

Intake is open and the advertising market for this tort has not reached the saturation levels seen in more mature mass tort categories. Firms entering with well-structured creative and a tight intake process are positioned to build dockets efficiently at this stage of the litigation cycle. MTAA monitors competitive density across the tort advertising landscape continuously and will give your team a current read on market conditions before campaign launch.

Ready to run Suboxone Tooth Decay campaigns?

We build, run, and qualify Suboxone Tooth Decay claimant-acquisition campaigns end to end. Book a call and we'll walk you through the creative, audience, and intake plan.

Book a strategy call